NaturoMed Therapeutics, the parent company of Stay Wyld Organics, is a vertically integrated functional and medicinal mushroom company. NaturoMed Therapeutics is currently producing bulk functional mushroom powders at its state of the art facility in BC, Canada and selling functional mushroom products to the retail market throughout North America. The company is committed to improving global mental and physical health through the production and distribution of high-quality Canadian grown organic mushroom products. NaturoMed is excited to announce that construction is well underway for its Health Canada Controlled Substances Dealer’s License to produce Psilocybin. Estimated completion is Q4, 2022. NaturoMed plans to produce Psilocybin once it receives the license. NaturoMed’s lead scientist is currently working on new extraction processes to create medicinal IP.
Similar Posts
Psychedelic Business Spotlight: July 30, 2021
This week in psychedelic business news: More psychedelic-assisted therapy clinics, recruitment begins in early DMT trial, and Filament gets more Health Canada love.
New Zealand Psychologist Assembles First Study Microdosing Cancer Patients with LSD
University of Auckland researcher hopes the psychedelic treatment will enhance the effect of psychotherapy, easing end-of-life distress in patients.
Psychedelic Business Spotlight – March 25
This week in psychedelic business news: Filament Health scores 2nd psilocybin patent; a new psychedelics company emerges as one crumbles.
A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial
Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research
Psychedelics Help Heal Childhood Trauma, Study Finds
Researchers find that there were significantly lower levels of complex trauma symptoms and feelings of internalized shame in study participants that had used psychedelics therapeutically.
Australia’s First Psychedelic Research Institute Opens with $40 Million Investment
Psychae Institute will collaborate with other clinical research organizations to develop novel psychedelic medicines and accompanying psychotherapeutic treatment models.